Gregory J. Riely on MET Exon 14 Skipping Mutations in Lung Cancer

Patients with NSCLC did not see a disease-free survival benefit with Imfinzi after surgery compared with taking a placebo.

February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.

Some patients with non-small cell lung cancer saw a 49% reduction in the risk of disease progression or death with ivonescimab versus Keytruda.

Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews

Dr. Debu Tripathy, editor-in-chief of CURE magazine, discusses the advancements made in small cell lung cancer.

Rybrevant plus Lazcluze, compared with Tagrisso, showed a trend towards favorable overall survival in EGFR-positive advanced non-small cell lung cancer.